01 August 2011
Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life
Annalisa PanicoABDE, Gelsy Arianna LupoliDE, Francesca MarcielloC, Roberta LupoliB, Marianna CacciapuotiE, Addolorata MartinelliF, Luciana GranieriF, Daniela IaconoB, Giovanni LupoliADEDOI: 10.12659/MSM.881905
Med Sci Monit 2011; 17(8): CR442-448
Abstract
Background: We studied the use of teriparatide in postmenopausal women with severe osteoporosis.
Material/Methods: Two groups (A and B) of patients affected by severe osteoporosis (T-score ≤–2.5 at bone mineral density were analyzed and 2 vertebral fractures on radiograph).
Group A was treated for 18 months with 20 µg/day of teriparatide. Group B was treated with bisphosphonates 70 mg/week. Every woman assumed 1 g of calcium and 800 IU of vitamin D3 daily. We evaluated the effects of therapy after 18 months (T18) from the beginning with bone turnover markers (alkaline phosphatase, procollagen type 1 N-terminal propeptide, and N-telopeptide cross-links) and dual-energy X-ray absorptiometry.
Results: Group A, at T18 procollagen type 1 N-terminal propeptide levels, increased 127%; bone alkaline phosphatase levels increased to 65%; N-telopeptide cross-links levels increased to 110%.
Group B, at T18 procollagen type 1 N-terminal propeptide levels, decreased to 74%; bone alkaline phosphatase levels decreased to 41%; N-telopeptide cross-links levels decreased to 72%.
After 18 months, lumbar bone mineral density increased to 12.4% and femoral bone mineral density increased to 5.2% in group A. Group B lumbar bone mineral density increased to 3.85% and femoral bone mineral density increased to 1.99%. Only a new vertebral fracture occurred in group A (2.4%), whereas 6 fractures occurred in group B (15.7%).
The quality of life questionnaire of the European Foundation for Osteoporosis (QUALEFFO) revealed a significant improvement in daily living, performed domestic jobs, and locomotor function in groups A and B.
Conclusions: The use of rhPTH in patients with severe osteoporosis offers more protection against fractures and improves the QoL more than bisphosphonates.
Keywords: Osteoporosis, Postmenopausal - drug therapy, Fractures, Bone - prevention & control, Cohort Studies, Bone and Bones - metabolism, Bone Density Conservation Agents - therapeutic use, Bone Density - drug effects, Biological Markers - metabolism, Alendronate - therapeutic use, Prospective Studies, Quality of Life, Spine - pathology, Teriparatide - therapeutic use
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
09 Apr 2024 : Clinical Research
Correlation between Thalamocortical Tract and Default Mode Network with Consciousness Levels in Hypoxic-Isc...Med Sci Monit In Press; DOI: 10.12659/MSM.943802
19 Apr 2024 : Clinical Research
Comparative Analysis of Postoperative Sagittal Balance in Expansive Open-Door Laminoplasty versus Laminecto...Med Sci Monit In Press; DOI: 10.12659/MSM.943057
20 Mar 2024 : Clinical Research
Prevalence and Management of Chronic Pain, Including Neuropathic Pain, in Dialysis Patients with End-Stage ...Med Sci Monit In Press; DOI: 10.12659/MSM.943808
15 Mar 2024 : Clinical Research
Impact of Cluster Nursing Intervention on ICU Patients' Psychological Well-Being and Complications Associat...Med Sci Monit In Press; DOI: 10.12659/MSM.942855
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952